Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
09 October 2012Website:
http://www.regulusrx.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 22:15:01 GMTDividend
Analysts recommendations
Institutional Ownership
RGLS Latest News
Continued mechanistic dose response observed following completion of 3 mg/kg dose level based on urinary biomarker analyses Percent change from baseline in PC1 and PC2 demonstrated a dose response across all doses tested, with statistical significance seen at 3 mg/kg compared to placebo Exploratory imaging analyses indicated reduction in total kidney volume in 70% of patients dosed with 3 mg/kg Fourth cohort enrollment underway Company to hold conference call at 8:30am ET today SAN DIEGO , June 24, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from the third cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. The Phase 1b MAD study is a double-blind, placebo-controlled trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics (PK/PD) of RGLS8429 in adult patients with ADPKD.
SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it expects to be added to the broad-market Russell 3000® Index and the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization.
On May 16, 2024, Regulus Therapeutics Inc. (Nasdaq: RGLS) promoted Rekha Garg, M.D., M.S., to Chief Medical Officer.
Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.
Long-established in the Biotechnology industry, Regulus Therapeutics Inc ( RGLS , Financial) has enjoyed a stellar reputation. It has recently witnessed a surge of 13.27%, juxtaposed with a three-month change of 4.18%.
Regulus (RGLS) surges as it completes enrollment in the first cohort to evaluate RGLS8429 for kidney disease.
What type of business is Regulus Therapeutics?
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
What sector is Regulus Therapeutics in?
Regulus Therapeutics is in the Healthcare sector
What industry is Regulus Therapeutics in?
Regulus Therapeutics is in the Biotechnology industry
What country is Regulus Therapeutics from?
Regulus Therapeutics is headquartered in United States
When did Regulus Therapeutics go public?
Regulus Therapeutics initial public offering (IPO) was on 09 October 2012
What is Regulus Therapeutics website?
https://www.regulusrx.com
Is Regulus Therapeutics in the S&P 500?
No, Regulus Therapeutics is not included in the S&P 500 index
Is Regulus Therapeutics in the NASDAQ 100?
No, Regulus Therapeutics is not included in the NASDAQ 100 index
Is Regulus Therapeutics in the Dow Jones?
No, Regulus Therapeutics is not included in the Dow Jones index
When does Regulus Therapeutics report earnings?
The next expected earnings date for Regulus Therapeutics is 08 August 2024